Clinical Trial Update: Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

View source ↗

Summary

The LIFE ACTIVE study evaluating physical activity levels in patients with Hemophilia A treated with damoctocog alfa pegol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Damoctocog alfa pegol (damoctocog alfa pegol)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Status: COMPLETED